Image Description (Desvenlafaxine Tablets Figure 1)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-2512
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-2512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Desvenlafaxine Tablets Figure 2)
This text provides information about changes in ketoconazole levels due to CYP3A4 inhibitors. It includes geometric mean ratio values with confidence intervals for Cmax and shows the relative change compared to the reference. This data can be used for evaluating the impact of these inhibitors on drug metabolism.*
Image Description (Desvenlafaxine Tablets Figure 3)
Image Description (Desvenlafaxine Tablets Figure 4)
This text provides information on the estimated proportion of patients with relapse, with 40% of patients experiencing relapse. It also includes a graph showing the time to relapse in days from randomization for Desverla 50mg and Placebo.*
Image Description (Desvenlafaxine Tablets Figure 5)
This text provides data on the estimated proportion of patients with relapse over time in a study comparing Desvenlafaxine to a placebo. It includes a graph showing the time to relapse in days from randomization. The information is visualized using a bar graph with marks at 0, 50, 100, and 150 days, with a comparison between Desvenlafaxine and Placebo at the 200-day mark.*
Image Description (Desvenlafaxine Tablets Structure)
Label (Lbl713352512)
This is a description of Desvenlafaxine Extended-Release Tablets 100mg. The tablets are film-coated and each tablet contains 152mg of Desvenlafaxine Succinate equivalent to 100mg of Desvenlafaxine. The instructions advise keeping the medication out of reach from children and storing it between 20° to 25°C. It is important to swallow the tablets whole and not break, crush, dissolve, or chew them. The text also includes information for pharmacists to dispense Patient Package Inserts and Medication Guide. The tablets are part of a pharmaceutical product from Bryant Ranch Prepack, Inc. and manufactured by Rubicon Research Private Limited. The full details can be accessed using the link provided in the text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
